HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
Read original at benzingaStocks · News reference
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
Read original at benzingaUS stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
Read original at benzingaH World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
Read original at benzingaThe OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Read original at benzinga-SEC FIling
Read original at benzinga